



## PRESS RELEASE

10 July 2025 14:10:00 CEST

# Senzime announces that the second tranche in the directed share issue of MSEK 110 has been fully subscribed

Senzime AB (publ) ("Senzime" or the "Company") announced on 2 June 2025 the board of directors' resolution to carry out a directed share issue of up to 24,000,000 shares at the subscription price of SEK 4.60 per share (the "Share Issue"). Furthermore, Senzime announced on 12 June 2025 that the first tranche of the Share Issue had been fully subscribed. Subscription and allotment have now also been made for all newly issued shares in the second tranche of the Share Issue. Thus, the Share Issue is now fully subscribed and allotted.

As previously communicated, the Share Issue is being carried out in two separate tranches. The first tranche ("**Tranche 1**") comprised 23,300,000 shares and was issued by the board of directors based on the authorization received at the annual general meeting on 19 May 2025. Senzime announced on 12 June 2025 that all shares in Tranche 1 had been subscribed for.

The second tranche ("**Tranche 2**") comprises 700,000 shares – which, with the subscription price mentioned above, corresponds to approximately MSEK 3,2 – and was resolved by the board of directors, with subsequent approval by the extraordinary general meeting on 30 June 2025. The person entitled to subscribe for Tranche 2 was the board member Adam Dahlberg. All shares in Tranche 2 have now been subscribed for and allotted. Through Tranche 2, the number of shares in the Company increases by an additional 700,000, from 156,515,046 to 157,215,046. The Company's share capital increases by SEK 87,500, from SEK 19,564,380.75 to SEK 19,651,880.75.

The entire Share Issue has now been fully subscribed and allotted. Through the Share Issue, the total number of shares in the Company increases by 24,000,000, from 133,215,046 till 157,215,046 shares. The Company's share capital increases by SEK 3,000,000, from SEK 16,651,880.75 SEK till 19,651,880.75. The Share Issue results in a dilution of approximately 15.27 percent, based on the total number of shares in the Company following the completion of the Share Issue.

### Advisers

Zonda Partners has acted as financial advisor in connection with the Share Issue and Advokatfirman Lindahl has acted as legal advisor.

### For further information, please contact:

---

Philip Siberg, CEO of Senzime AB

Phone: +46 (0) 707 90 67 34, e-mail: [philip.siberg@senzime.com](mailto:philip.siberg@senzime.com)

Slavoljub Grujicic, CFO

Phone: +46 (0) 76 306 60 11, e-mail: [slavoljub.grujicic@senzime.com](mailto:slavoljub.grujicic@senzime.com)

## About Sensime

---

Sensime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Sensime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to recovery.

Headquartered in Uppsala, Sweden, Sensime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at [sensime.com](https://sensime.com).

## Attachments

---

**Sensime announces that the second tranche in the directed share issue of MSEK 110 has been fully subscribed**